nravelling the mechanism of action of low-dose glucocorticoids: a study of oral versus parenteral glucocorticoids.

• Conditions: Reumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis

• Registration Number: NL-OMON26487
• Lead Sponsor: VUmc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 35

Inclusion Criteria

Reumatoid arthritis, polymyalgia rheumatica or psoriatic arthritis according to the treating physician
-Elevated ESR (=30 mm/h)

Exclusion Criteria

Difficult to measure a decreased ESR
-Current or recent (<4 weeks previously) on any form of GC therapy
-For reumatoid arthritis and psoriatic arthritis patients, change of antirheumatic medication (DMARDs, biologics) in the 4 weeks before the assessment
-Known with other health conditions that can cause elevated ESR (e.g. hematologic disorders, infections, multiple myeloma, monoclonal gammopathy etc.)

Risk of harm
-Active disease necessitating (change of) treatment within weeks, according to treating physician
-Unstable medical condition causing contra-indication for GC, according to treating physician. For example active infection, unstable diabetes, malignant hypertension, etc.
-Signs or symptoms of temporal arteritis (according to the treating physician)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ESR

Secondary Outcome Measures

Name	Time	Method
C-reactive protein (CRP), cortisol, adrenocorticotropic hormone (ACTH) and disease activity (based on Rapid3 questionnaire). Stored serum samples may be used for further analysis of inflammatory cytokines as exploratory endpoints.